Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

Launched by THOMAS JEFFERSON UNIVERSITY · Apr 14, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new way to diagnose prostate cancer using a special ultrasound technique. The researchers want to see if a contrast agent called Definity, which appears as tiny bubbles on ultrasound images, can help doctors get clearer pictures of the prostate and more accurately identify cancer. This method is non-invasive, meaning it doesn’t require any surgery or painful procedures, and the bubbles used in the test quickly leave the body through breathing.

To participate in the trial, you need to be a male aged 18 or older who is scheduled for surgery to remove the prostate due to cancer. You should be willing to give your consent to have this ultrasound done before your surgery. However, if you have recently participated in another clinical trial, have allergies to the substances in Definity, or have received treatment for prostate cancer before, you may not be eligible. If you join the trial, you can expect to undergo the ultrasound with the contrast agent, which should help your doctors gather important information about your condition.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Subject must be scheduled for radical prostatectomy for treatment of prostate cancer
• • Subject must be able and willing to give written informed consent for a contrast enhanced ultrasound study of the prostate prior to prostatectomy
• • Subject must be a male at least 18 years of age when informed consent is obtained
• Exclusion Criteria:
• • Participant in a clinical trial involving an investigational drug within the past 30 days
• • Patients with known or suspected hypersensitivity to perflutren, PEG, or any other component of Definity
• • Previous treatment for prostate cancer, including hormone therapy
• • Clinically unstable, severely ill, or moribund as per treating physician